Research programme : anti-fibrotic therapeutics - ProMetic Life Sciences

Drug Profile

Research programme : anti-fibrotic therapeutics - ProMetic Life Sciences

Alternative Names: PBI-4425; PBI-4547

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator ProMetic Life Sciences
  • Class Small molecules
  • Mechanism of Action Cell differentiation modulators; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; Immunomodulators; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic nephropathies; Hepatic fibrosis; Idiopathic pulmonary fibrosis

Most Recent Events

  • 20 Apr 2017 Prometic Life Sciences plans a clinical trial for PBI 4547 for Non-alcoholic steatohepatitis
  • 30 Mar 2017 Prometic Life Sciences and Shenzhen Royal Asset Management enter agreement to form joint venture company for development, manufacturing and commercialisation of PBI 4547 and PBI 4425
  • 13 Apr 2016 Preclinical trials in Hepatic fibrosis in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top